ArticleCancer discovery2024

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.

Brandie C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.